X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. is a biopharmaceutical company that researches, develops, and commercializes new treatments for rare immune system diseases. The company's primary product is XOLREMDI, an orally administered small-molecule selective antagonist of the chemokine receptor CXCR4. XOLREMDI is currently in a Phase 3 clinical trial for treating patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. X4 Pharmaceuticals has several licensing agreements for XOLREMDI. It has an agreement with Abbisko Therapeutics Co Ltd. for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, manufacturing, and commercialization of mavorixafor (XOLREMDI) in Europe, Australia, and New Zealand. Additionally, the company has a license agreement with Genzyme Corporation for the CXCR4 receptor, allowing Genzyme to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic, and diagnostic uses. X4 Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.